Suppr超能文献

非营利性药物研发正处于十字路口。

Non-profit Drug Research and Development at a Crossroads.

机构信息

Public Health Department - Research Unit EA 3279, Aix-Marseille University, 27 bd Jean Moulin, 13385, Marseille, France.

Claude Bernard University, Laboratoire Parcours Santé Systémique EA 4129, Lyon, France.

出版信息

Pharm Res. 2018 Feb 7;35(3):52. doi: 10.1007/s11095-018-2351-3.

Abstract

In wealthy nations, non-profit drug R&D has been proposed to reduce the prices of medicines. We sought to review the ethical and economic issues concerning non-profit drug R&D companies, and the possible impact that their pricing strategy may have on the innovation efforts from for-profit companies targeting the same segment of the pharmaceutical market. There are two possible approaches to pricing drugs developed by non-profit R&D programs: pricing that maximises profits and "affordable" pricing that reflects the cost of manufacturing and distribution, plus a margin that ensures sustainability of the drug supply. Overall, the non-profits face ethical challenges - due to the lack of resources, they are unable to independently commercialize their products on a large scale; however, the antitrust law does not permit them to impose prices on potential licensees. Also, reduced prices for the innovative products may result in drying the for-profit R&D in the area.

摘要

在富裕国家,有人提议进行非营利性药物研发,以降低药品价格。我们试图对非营利性药物研发公司的伦理和经济问题进行综述,以及它们的定价策略可能对针对同一医药市场部分的营利性公司的创新努力产生的影响。非营利性研发项目开发的药物有两种可能的定价方法:一是使利润最大化的定价,二是反映制造成本和分销成本,加上确保药品供应可持续性的利润的“负担得起”的定价。总体而言,非营利组织面临着伦理挑战——由于资源匮乏,它们无法独立大规模地将其产品商业化;然而,反垄断法不允许它们对潜在被许可方施加价格。此外,创新产品降价可能导致该领域营利性研发枯竭。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验